| 1 | Mirikizumab (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [3] 37 37, 96, 97 💬
|
| 2 | Mirikizumab (MIR) (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 3 | Mirikizumab - Intravenous (IV) (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
| 4 | Mirikizumab - IV (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 5 | Mirikizumab - SC (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 6 | Mirikizumab - Subcutaneous (SC) (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
| 7 | Mirikizumab IV (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 97 97 💬
|
| 8 | Mirikizumab SC (D11123) | [1] Mirikizumab Mirikizumab | [1] Mirikizumab
Mirikizumab
(D11123) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 97 97 💬
|